Skip to main content

Table 3 Guidelines/local working group recommendations consulted for treatment of relapsed or refractory Ph(–) B-precursor ALL

From: Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Guideline or local working group recommendation

Number of respondents consulting for treatment n (%)a

 

France

Germany

Italy

Spain

UK

Total

N = 15

N = 15

N = 15

N = 15

N = 15

N = 75

ASH/ASCO, US

9 (60)

3 (20)

7 (47)

6 (40)

4 (27)

29 (39)

EWALL, Europe

7 (47)

1 (7)

2 (13)

2 (13)

7 (47)

19 (25)

NCCN, US

6 (40)

1 (7)

5 (33)

5 (33)

 

17 (23)

GMALL, Germany

1 (7)

13 (60)

1 (7)

1 (7)

 

16 (21)

GIMEMA, Italy

  

12 (80)

1 (7)

 

13 (17)

PETHEMA, Spain

   

11 (73)

1 (7)

12 (16)

UKALL XII, UK

  

1 (7)

 

11 (73)

12 (16)

HAS, France

2 (13)

    

2 (3)

Othersb

4 (27)

   

3 (20)

7 (9)

  1. aRespondents could select multiple guidelines
  2. bThe following guidelines and/or local working group recommendations were consulted by one respondent for treatment: COOPRALL, France; Onco LR, France; GELA, France; GRAALL, France; BCSH, UK; The Beatson hospital, UKc; UKALL 2011 for young adults, UK; non-specified protocol
  3. cThe Beatson hospital is a cancer centre located in the West of Scotland
  4. ALL, acute lymphoblastic leukaemia; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; BCSH, the British Committee for Standards in Haematology; COOPRALL, Protocole Coopérateur de Traitement des Rechutes de Leucémies Aiguës Lymphoblastiques de L’enfant (treatment protocol for relapse of ALL in children); EWALL, European Working group for Adult Lymphoblastic Leukemia; GELA, Groupe d’Etude des Lymphomes de l’Adulte (Study Group of the Adult Lymphoma); GET-LALA, Groupe d’Etude et de Traitement des Leucémie Aiguës Lymphoblastique de l’Adulte (Group for the Study and Treatment of Adult ALL, France); GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adultodell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German Multicenter Study Group for Adult ALL; GOELAMS, Groupe Ouest Est des Leucémies Aiguës et Maladies du Sang (East West Group of Acute Leukemia and Blood Diseases, France); GRAALL, Cooperative group combining the French GET-LALA, the GOELAMS, and the SAKK; HAS, Haute Autorité de Santé (High Authority for Health); NCCN, the National Comprehensive Cancer Network; Onco LR, le réseau régional de Cancérologie en Languedoc Roussillon (regional network of Oncology in Languedoc Roussillon); PETHEMA, Program for Study and Treatment of Malignant Haemopathies, Spanish Society of Haematology; SAKK, Schweizer Arbeitsgemeinschaft für klinische Krebsforschung, Leukämie-Arbeitsgruppe (Swiss Group for Clinical Cancer Research, Leukemia Working Group); UKALL 2011 for young adults, United Kingdom Trial for children and young adults with Acute lymphoblastic Leukaemia and Lymphoma 2011; UKALL XII, Medical Research Council Acute Lymphoblastic Leukemia Trial XII